| Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML) (NCT04777916) | Acute Leukemia French Association | 2022-04-14 |
| Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia (NCT06760260) | Hrain Biotechnology Co., Ltd. | 2022-01-26 |
| ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN (NCT04639024) | Gwynn Long, M.D. | 2021-12-07 |
| Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell Transplantation (NCT04886206) | Nantes University Hospital | 2021-11-10 |
| Feasibility Pilot Exploring Variability in Biomarkers and PROs in AML (NCT04908852) | Dana-Farber Cancer Institute | 2021-07-26 |
| Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome (NCT04912063) | AbbVie | 2021-06-25 |
| VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) (NCT04702425) | Novartis Pharmaceuticals | 2021-06-23 |
| Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of Any Age With Acute Myeloid Leukemia (NCT04813263) | AbbVie | 2021-05-28 |
| A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant (NCT04872595) | Memorial Sloan Kettering Cancer Center | 2021-04-30 |
| Pharmacokinetics, Tolerability and Safety of NEX-18a (NCT05048498) | Nanexa AB | 2021-04-27 |
| Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants Above 19 Years of Age With Acute Myeloid Leukemia (AML) (NCT04826523) | AbbVie | 2021-04-05 |
| A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated (NCT04716114) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-03-24 |
| GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies (NCT04824794) | Genmab | 2021-03-09 |
| Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of Leukemia Relapse in Children Given Haploidentical Hematopoietic Stem Cell Transplantation (NCT06865352) | Fondazione IRCCS Policlinico San Matteo di Pavia | 2021-02-13 |
| Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML) (NCT04547062) | Nantes University Hospital | 2020-12-29 |
| Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia (NCT04250051) | Northwestern University | 2020-12-21 |
| Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations (NCT04603001) | Eli Lilly and Company | 2020-11-19 |
| Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM) (NCT04395092) | Kiadis Pharma | 2020-11-13 |
| A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy (NCT04266795) | Takeda | 2020-10-13 |
| A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML) (NCT04509622) | AbbVie | 2020-10-05 |
| Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML) (NCT05488613) | Novartis Pharmaceuticals | 2020-09-24 |
| A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) (NCT04240002) | Astellas Pharma Global Development, Inc. | 2020-09-04 |
| Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies (NCT05513612) | Shanghai Pudong Hospital | 2020-08-01 |
| JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation (NCT04429191) | Jasper Therapeutics, Inc. | 2020-07-08 |
| A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. (NCT04275518) | Ascentage Pharma Group Inc. | 2020-07-06 |
| A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers (NCT04272203) | AbbVie | 2020-05-05 |
| A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (NCT04102020) | AbbVie | 2020-03-26 |
| A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (NCT04202003) | TJ Biopharma Co., Ltd. | 2020-03-25 |
| A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leukemia Participants Ineligible for Standard Induction Therapy in Russian Federation (NCT04253314) | AbbVie | 2020-03-13 |
| A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) (NCT04161885) | AbbVie | 2020-02-26 |
| Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT (NCT04284228) | NexImmune Inc. | 2020-02-20 |
| Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (NCT04230265) | AvenCell Europe GmbH | 2020-01-28 |
| A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors (NCT04029688) | Hoffmann-La Roche | 2020-01-27 |
| Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy (NCT03969420) | Sumitomo Pharma America, Inc. | 2020-01-15 |
| Remote Outpatient Temperature Monitoring for Early Detection of Febrile Neutropenia After Chemotherapy (NCT04081753) | Augusta University | 2019-12-16 |
| A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies (NCT06550713) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-10-22 |
| A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy (NCT03941964) | AbbVie | 2019-08-15 |
| HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) (NCT03940352) | Novartis Pharmaceuticals | 2019-06-24 |
| A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) (NCT03730012) | Astellas Pharma Global Development, Inc. | 2019-06-19 |
| Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML (NCT03922100) | Nerviano Medical Sciences | 2019-04-03 |
| TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies (NCT03849651) | St. Jude Children's Research Hospital | 2019-01-31 |
| The Role and Mechanism of TCR-T Cells in Immunotherapy for Acute Myeloid Leukemia (NCT06904859) | Shenzhen University General Hospital | 2019-01-01 |
| Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML (NCT04402723) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2018-11-06 |
| Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) (NCT03723681) | Daiichi Sankyo Co., Ltd. | 2018-11-05 |
| Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN (NCT03613532) | Jacqueline Garcia, MD | 2018-10-24 |
| A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia (NCT03625505) | AbbVie | 2018-10-18 |
| Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD) (NCT03699384) | Memorial Sloan Kettering Cancer Center | 2018-10-03 |
| Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors (NCT03615105) | Memorial Sloan Kettering Cancer Center | 2018-07-25 |
| A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML) (NCT03512197) | Novartis Pharmaceuticals | 2018-07-20 |
| Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML (NCT03709576) | Milton S. Hershey Medical Center | 2018-07-18 |
| A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML (NCT03547115) | MEI Pharma, Inc. | 2018-05-31 |
| A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia (NCT03441555) | AbbVie | 2018-05-30 |
| A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer (NCT03360006) | AbbVie | 2018-03-16 |
| A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML) (NCT03125876) | Sunshine Lake Pharma Co., Ltd. | 2017-11-13 |
| A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies (NCT03236857) | AbbVie | 2017-11-08 |
| IDH1/IDH2 Mutation Frequency in Acute Myeloblastic Patients (NCT03204838) | Hospital General de Mexico | 2017-07-10 |
| A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy (NCT03069352) | AbbVie | 2017-05-23 |
| Allogeneic HCT Using Conditioning Regimen of BuFluATG for AML CR1 (NCT07155382) | Asan Medical Center | 2017-04-04 |
| A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy (NCT02993523) | AbbVie | 2017-02-02 |
| Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome (NCT02749708) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2017-01-30 |
| A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission (NCT02927262) | Astellas Pharma Global Development, Inc. | 2017-01-10 |
| Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases (NCT01962636) | Masonic Cancer Center, University of Minnesota | 2016-12-01 |
| Leukemia Stem Cell Detection in Acute Myeloid Leukemia (NCT02927938) | Wake Forest University Health Sciences | 2016-09-01 |
| A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia (NCT02826642) | Novartis Pharmaceuticals | 2016-08-26 |
| A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy (NCT02752035) | Astellas Pharma Global Development, Inc. | 2016-08-01 |
| Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation (NCT02790515) | St. Jude Children's Research Hospital | 2016-07-14 |
| Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY (NCT02992860) | GWT-TUD GmbH | 2016-07-01 |
| Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML (NCT02781883) | Bio-Path Holdings, Inc. | 2016-05-01 |
| Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia (NCT02658487) | Vanderbilt-Ingram Cancer Center | 2016-03-01 |
| The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients (NCT02648932) | University of Chicago | 2016-02-04 |
| Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) (NCT02198482) | University of Ulm | 2016-02-01 |
| Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications (NCT02649790) | Karyopharm Therapeutics Inc | 2016-01-01 |
| Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome (NCT01520805) | Cornerstone Pharmaceuticals | 2016-01-01 |
| Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS (NCT02626715) | Randy Windreich | 2015-09-04 |
| Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation (NCT02492737) | Agios Pharmaceuticals, Inc. | 2015-08-07 |
| Treatment of Elderly AML Patients With Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells From Haploidentical Related Donors (NCT02519712) | Memorial Sloan Kettering Cancer Center | 2015-07-28 |
| Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML (NCT02532010) | Weill Medical College of Cornell University | 2015-06-15 |
| Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients (NCT02433483) | St. Jude Children's Research Hospital | 2015-05-22 |
| A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer (NCT02391480) | AbbVie | 2015-04-14 |
| Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment (NCT02269579) | Jazz Pharmaceuticals | 2015-04-01 |
| Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS (NCT02204020) | University of Pittsburgh | 2015-04-01 |
| Study of Ibrutinib in Subjects With Acute Myeloid Leukemia (NCT02351037) | Pharmacyclics LLC. | 2015-02-01 |
| Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR (NCT02416388) | University Hospital, Angers | 2015-01-01 |
| Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML (NCT02255162) | Massachusetts General Hospital | 2015-01-01 |
| "InDACtion" vs "3+7" Induction in AML (NCT02172872) | European Organisation for Research and Treatment of Cancer - EORTC | 2014-11-28 |
| Yoga Fatigue Study (NCT02134782) | The Hospital for Sick Children | 2014-10-02 |
| 10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1 (NCT02252107) | Radboud University Medical Center | 2014-10-01 |
| Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation (NCT02259348) | St. Jude Children's Research Hospital | 2014-10-01 |
| Study Evaluating Venetoclax in Subjects With Hematological Malignancies (NCT02265731) | AbbVie | 2014-09-22 |
| Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia (NCT02113982) | Stemline Therapeutics, Inc. | 2014-09-01 |
| Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome (NCT02212561) | St. Jude Children's Research Hospital | 2014-08-01 |
| An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients (NCT02238925) | Jazz Pharmaceuticals | 2014-07-01 |
| Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) (NCT02013648) | University of Ulm | 2014-07-01 |
| Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT02181660) | Astellas Pharma Inc | 2014-06-16 |
| Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review (NCT03047083) | Astellas Pharma Global Development, Inc. | 2014-06-02 |
| Study of the Glutaminase Inhibitor CB-839 in Leukemia (NCT02071927) | Calithera Biosciences, Inc | 2014-03-01 |
| Selinexor (KPT-330) in Older Patients With Relapsed AML (NCT02088541) | Karyopharm Therapeutics Inc | 2014-03-01 |
| Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Patients (NCT01999413) | French Innovative Leukemia Organisation | 2013-11-01 |
| Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT (NCT01772953) | Center for International Blood and Marrow Transplant Research | 2013-09-01 |
| Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients (NCT01929408) | Fred Hutchinson Cancer Center | 2013-07-19 |